Although the past year has experienced a series of challenges, such as national negotiations, clinical substitution, tax reduction and price reduction, and “4 + 7” purchasing with volume, the sales scale of terminal powders in domestic Phenibut hospitals has maintained a growth momentum in 2019 Phenibut powder wholesale.
In 2019, a total of 2613 domestic sample hospitals and 2642 enterprises were involved. The overall market sales rose from 152.4 billion yuan in 2012 to 228.4 billion yuan in 2019, an increase of 2.74% over the same period. The total amount of hospital terminal market has warmed up slightly. With the Phenibut expansion of purchasing scope with volume, the price of powders will decrease,Phenibut on sale or the total amount of powders will be affected to some extent. In the future, the total amount of sample hospitals will increase or continue to be under pressure.
TOP 10 treatment accounted for 86%.
In 2019, from the perspective of the sample hospital treatment field, the top 10 treatment areas were 196.4 billion yuan, accounting for 86.0% of the overall market. The top five treatment areas are anti-infective powders, cardiovascular system powders, blood and hematopoietic system powders, nervous system powders and anti-cancer powders. The total amount of powder use has exceeded 20 billion yuan,Phenibut powder totaling 132.1 billion yuan. Among them, the growth of anti-cancer powders is faster than that of the same period.